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Stem cells have been studied for many years for their potential to repair damaged organs in the human body.
Although many different mechanisms have been suggested as to how stem cells may initiate and facilitate repair
processes, much remains unknown. Recently, there has been considerable interest in the idea that stem cells may
exert their effects in vivo via paracrine actions. This could involve the release of cytokines, growth factors or
secreted extracellular vesicles. This article reviews the role that paracrine actions may play in tissue regeneration. In
particular, it considers how microvesicles, as a mediator or modulator of paracrine action, can be exploited as a tool
for non-cell-based therapies in regenerative medicine.
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The potentially advantageous effects of using stem cells
in tissue regeneration were first demonstrated by Till
and McCulloch in the 1960s [1,2]. This pivotal discovery
paved the way for regenerative medicine, which in the
last decade has advanced significantly. Regenerative
medicine is broadly defined as the study of the repair, re-
placement, regeneration and restoration of diseased,
damaged or aged cells, tissues or organs [3,4]. It has
emerged as a serious solution to the repair of end-stage
organ damage and to address the growing shortfall in
donor organs for transplantation. Its clinical use is still
very much in its infancy and much remains to be deter-
mined about the mechanisms of action for cellular ther-
apeutics. In this review, we will attempt to summarise
some of the current state-of-the-art information avail-
able in this field, with an emphasis on mesenchymal
stem cells and other non-embryo-derived cellular ther-
apies, which are advancing rapidly towards the clinic,
with special reference to paracrine-mediated tissue
repair.
The first successful demonstration of regenerative
medicine, using a cell-based therapy to repair damaged
tissue, was described by Ferrari et al. [5]. This group* Correspondence: Paul.Shiels@glasgow.ac.uk
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distribution, and reproduction in any mediumshowed that regeneration of damaged muscle fibres was
possible by transplanting bone marrow stem cells into
injured muscle tissue [5]. Subsequently, a variety of dif-
ferent stem cell types has been isolated and investigated
for use in tissue regeneration, with varying degrees of
success. These include mesenchymal stem cells (MSCs)
[6-9], adipose-derived stem cells (ASCs), also known as
adipose-derived MSCs [10], embryonic stem cells (ESCs)
[11], endothelial progenitor cells (EPCs) [12] and cardiac
stem cells (CSCs) [13] (see Figure 1 for general proper-
ties of stem cells). Amongst the many choices available
at present, MSCs have been the most favoured for the
majority of published studies. MSCs are primarily iso-
lated from the bone marrow, but they can also be de-
rived from other tissue sources. Their popularity with
researchers lies in a number of inherently advantageous
properties, including easily identifiable cell surface mark-
ers, their adhesiveness to plastic facilitating culture
ex vivo and their ability to differentiate into multiple cell
lineages. Moreover, they can be sourced from an adult;
hence, they are free from the ethical issues around re-
search using ESCs [6]. More recently, pathfinder cells
(PCs), a novel cell population named for their ability to
navigate a path towards the site of damaged tissues
in vivo, have been described [14-17].
Although there has been a great deal of discussion
about how stem cells contribute to the regeneration of
damaged tissues, much remains to be understood. OneCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Overview of the general properties of stem cell types. The chart shows the different types of available stem cells and the surface
markers used to identify cells of both adult and embryonic origin as well as other stem cell types.
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tissue is by means of differentiation of the stem cells into
tissue-specific cell types [18,19]. Others have suggested
that stem cells fuse with host cells in order to replace
damaged tissue [20,21]. A more recent suggestion is that
these cells work via paracrine signalling, instead of direct
differentiation or fusion between cells. Paracrine signal-
ling may act to stimulate damaged target cells to prolif-
erate [22] or may induce other local cell types to
differentiate [16]. The purpose of this review article is to
provide an overview of the role that paracrine factors
may play in various tissue damage models and how we
can exploit this for the future treatment of disease.
Paracrine action of stem cells in disease models
The idea that stem cells work via a paracrine action is
now more widely accepted. Understanding paracrine sig-
nalling by cells involved in the repair of damaged tissue
is important to the implementation of any future regen-
erative therapies. Paracrine signalling is defined as a
form of communication between two different cells,
where one cell releases chemical mediators to its imme-
diate environment, which results in a change in the be-
haviour of a cell in its adjacent environment. There arenumerous suggestions as to how the paracrine effects
observed in many different model tissue repair systems
are mediated. However, none has yet proven definitive.
The protective and regenerative effects of different
stem cell therapies have been attributed to paracrine ac-
tion in many cardiovascular studies. Coronary artery dis-
ease and heart failure are a leading cause of mortality
and morbidity, particularly in the developed world. Con-
sequently, many investigators have focused their efforts
in this area of research. It has been proposed that para-
crine effects contribute to the improvement of cardiac
function following tissue insult and injury by modifying
various factors such as inflammation, fibrosis, apoptosis,
neovascularisation, contractility and cardiac repair [23].
A study that transplanted human cardiac progenitor cells
(hCPCs) into a mouse model of myocardial infarction (MI),
found that hCPCs isolated following transplantation using
laser capture micro-dissection, had significantly increased
expression of growth factors, such as vascular endothelial
growth factor (VEGF), fibroblast growth factor 2 (FGF2)
and connective tissue growth factor in vivo [24]. The
transplanted hCPCs stained negatively for cardiac and
endothelial differentiation markers, indicating that no dif-
ferentiation of hCPCs had occurred [24]. Furthermore,
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excitation-contraction coupling [9]. The authors of this
study suggested that this was solely mediated via a para-
crine mechanism, attributed to a phosphoinositide-3-kinase
(PI3K)/Akt induced change in calcium signalling and an
endothelial nitric oxide synthase (eNOS) mediated change
in sarco-endoplasmic reticulum calcium transport ATPase
(SERCA) activity, and not by inter-communication between
the MSCs and cardiomyocytes.
Additionally, one group [25] demonstrated that incuba-
tion of cardiomyocytes subjected to hypoxia and re-
oxygenation with conditioned media from MSCs resulted
in a cardio-protective effect. They suggested that this was
due to a paracrine effect from the MSC-conditioned
media, which protected the cells from damage by modu-
lating the effect of a mitochondrial apoptotic pathway to
reduce apoptosis via the inhibition of cytochrome C re-
lease from the mitochondria and by reducing activation of
caspase-3 [25]. The protective effect of MSCs was also evi-
dent in a study using a rat model of pulmonary arterial
hypertension (PAH). In this study [26], the authors dem-
onstrated that sublingual vein injection of MSCs for two
weeks resulted in improved lung and heart function fol-
lowing injury, improved pulmonary vascular remodelling,
reduced inflammation and enhanced angiogenesis. These
researchers suggested that these findings were possib-
ly the result of a paracrine mechanism via secretion of
anti-inflammatory mediators, as they observed reduced
expression of inflammatory mediators, such as IL-1β, IL-6,
TNF-α and matrix metallopeptidase-9 (MMP-9), but
higher levels of VEGF, in their MSC-treated group com-
pared to untreated groups [26].
Recently published work [27] has suggested a potential
role for microRNAs in cardiac regeneration effects.
These researchers found that adult rat cardiomyocytes
with limited capacity for differentiation can be induced to
enter the cell cycle and proliferate by the exogenous admin-
istration of microRNAs, hsa-mir-590 and hsa-miR-199a,
in both in vivo and in vitro experimentation [27].
MicroRNAs are small RNAs of approximately 21 to 25
nucleotides that negatively regulate gene expression
post-transcriptionally and which can affect the function
of diverse biological processes [28]. MicroRNAs have
been shown to be released by cells in small vesicles,
such as microvesicles and exosomes, which will be
discussed in more detail below.
The use of stem cells, particularly MSCs, in recovery
from acute kidney injury (AKI) has also been extensively
studied. Ischaemia/reperfusion (I/R) injury is known to
cause delayed cellular regeneration and functional recov-
ery following kidney transplantation [29]. It has been
suggested that the reno-protective effect of administered
MSCs in rats with I/R AKI was mediated primarily by
the paracrine action of MSCs [30]. Significantly, theseinvestigators found: (i) increased secretion of growth fac-
tors and upregulation of cytokines such as hepatocyte
growth factor (HGF), VEGF, insulin-like growth factor-1
(IGF-1), IL-10, basic FGF, tumour growth factor alpha
(TGF-α) and B-cell lymphoma-2 (Bcl-2), which are anti-
inflammatory, anti-apoptotic and known to improve
renal function; (ii) downregulation of pro-inflammatory
mediators such as IL-1β, TNF-α, IFN-γ and inducible ni-
tric oxide synthase (iNOS) and (iii) little to no intra-
renal trans-differentiation events of administered MSCs
[30]. Furthermore, they also demonstrated in a second
study that MSC-conditioned media increased cell sur-
vival and the proliferation rate of endothelial cells
in vitro and proposed that the vasculo-protective effect
of MSCs was due to their ability to interact with endo-
thelial cells by complex paracrine actions, which are able
to protect and regenerate damaged vasculature in AKI
significantly [7].
Wound healing is another area of research in which
the possible effects of paracrine signalling by stem cells
have been explored. Impairment of normal wound-
healing processes often occurs in diabetic patients,
leading to chronic wounds. These do not heal and can
subsequently become gangrenous lesions or diabetic
ulcers, often requiring the need for amputation. Thus,
advancement of any regenerative therapy to repair such
wounds and to promote fast healing would be beneficial.
However, balance is needed between promoting fast
wound healing and the formation of fibrous scar tissue,
which could impair the function of the healed tissue or
have a poor cosmetic appearance. One study [31] found
that MSC-conditioned media accelerate wound-healing
processes. Further investigations revealed that the
medium contained high levels of growth factors and
chemokines known to promote wound-healing. These
included epidermal growth factor (EGF), keratinocyte
growth factor (KGF), IGF-1, VEGF-α, erythropoietin
(EPO), stromal cell-derived factor 1 (SDF-1), macro-
phage inflammatory protein (MIP)-1a and MIP-1b,
suggesting that MSCs may work by a paracrine mechan-
ism to accelerate wound healing [31]. MSCs have also
been shown to release anti-fibrotic cytokines, which
reduce the formation of scar tissue [32]. It has been
suggested that foetal aorta-derived CD133+ progenitor
cells (and a conditioned medium from their culture)
also act similarly in a model of ischaemic diabetic-
induced ulceration [33]. These researchers found that
CD133+ cells accelerated wound closure and promoted
angiogenesis via a paracrine effect through the release of
cytokines, which affect the Wnt pathway, leading to
stimulation of endothelial cell proliferation, migration
and survival [33]. More recently, adipose-derived MSCs
have also been used to demonstrate this effect in cutane-
ous wound healing [34].
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been noted in experiments using MSCs to induce repair
processes in spinal cord injury in rats [35]. Even after 21
days of observations, the MSCs had not directly become
incorporated into the regenerated host tissue, though
there was a significant improvement in functional recov-
ery from as early as a week after MSC treatment, sug-
gesting an MSC-mediated paracrine effect [35]. The use
of MSCs in spinal cord injury has been extensively
reviewed elsewhere by Wright et al. [36].
Recently, a study [16] showed regeneration of damaged
adult pancreatic tissue and complete long-term func-
tional recovery using a xeno-transplant model, whereby
streptozotocin-induced diabetic mice were injected with
rat or human PCs. PCs are a novel adult cell type, lack-
ing the standard MSC markers CD105 and CD73 [15].
Crucially, the regenerated pancreatic tissue was not a re-
sult of the trans-differentiation of rat or human PCs into
fully functional mouse pancreatic islets [16]. Instead, it
was proposed that the recovery observed was more likely
the result of a paracrine signal from the PCs [16]. Not-
ably, this effect was not observed with the use of a PC-
conditioned medium in this model, suggesting that it
was not the result of cytokine or growth factor secre-
tions, though this lack of efficacy might formally be due
to a dose effect. PCs have subsequently been shown to re-
pair renal damage resulting from ischaemic injury in a
similar xeno-transplant model [17]. The low numbers of
PCs or PC-derived cells found in the repaired kidney is
again consistent with paracrine-mediated repair processes.
From the aforementioned experiments, it is evident
that there is agreement amongst many researchers, tack-
ling a diverse range of disease models, which clearly in-
dicates the role that paracrine actions, as opposed to
stem cell differentiation or cell fusion, have in repairing
damaged tissues. Stem cells have been shown to target
various local cells to exert their effects. For example,
MSCs have been known to modulate the immune sys-
tem by inducing immune cells, such as regulatory T
cells, B-lymphocytes, natural killer (NK) cells and den-
dritic cells, and generating a regulatory phenotype of
macrophages [37] while PCs affect pancreatic beta cells
and are also immunomodulatory [16]. However, there
still remains a need to further elucidate the precise
mechanisms by which stem and progenitor cells initiate
the repair of damaged tissues via paracrine actions.
Aside from the observation that stem cells release a
multitude of growth factors and cytokines to induce the
reparative process, one exciting discovery is that these
cells release microvesicles and exosomes, which may be
a source of paracrine factors required for tissue repair
and which may ultimately be used as therapeutic source
material directly. Indeed, the recent discovery of a po-
tential role for microRNAs, which occur in microvesiclesand are one of the paracrine factors able to initiate re-
pair processes in damaged cardiac tissue, adds another
important dimension into the possibilities for thera-
peutic intervention [27].
Microvesicles as mediators of paracrine effects
One of the most rapidly emerging ideas that explain
paracrine mechanisms of tissue regeneration is the use
of stem cell-derived micro-secretory vesicles, which act
as mediators of tissue regeneration following injury or
disease. This is an exciting area of research, as it opens
up the potential to explore non-cell-based therapy in re-
generative medicine.
Micro-secretory vesicles include microvesicles, which
are one of a number of membranous vesicles derived
from cells that were previously thought of as artifactual,
resulting from cell preparatory methods or from cellular
debris without any specific biological purpose. Recent
evidence, however, has shown that microvesicles possess
the ability to participate and influence numerous bio-
logical processes [38]. It is now generally accepted that
microvesicles could aid in the transfer of genetic infor-
mation between cells, as they contain proteins, messen-
ger RNAs (mRNAs), DNAs and/or microRNAs. They
also regulate the physiology and pathophysiology of cells
and can be exploited for therapeutic and diagnostic pur-
poses [38-41]. Thus, microvesicles could be a useful tool
to treat solid organ damage as they may act as mediators
to promote anti-inflammatory, pro-angiogenic, anti-
apoptotic and differentiation or mitotic factors to acti-
vate the intrinsic repair and regeneration processes.
There remains controversy surrounding the nomencla-
ture for micro-secretory vesicles such as microvesicles
and exosomes, based on their size and their isolation
methodologies. Whilst agreement needs to be reached
on a standard definition for these vesicles, it is widely
understood and accepted that both of these types of
vesicle are structurally and morphologically distinct
(Figure 2). A microvesicle arises from budding of the
plasma membrane of a cell. Microvesicles are generally
more heterogeneous in terms of size, which can range
from anywhere between 100 nm and 1,000 nm. Con-
versely, exosomes are derived from an endocytosis
process within cells and are more homogeneous with re-
spect to vesicle size, ranging from 30 nm to 100 nm
[42,43]. It has been suggested that microvesicles will
sediment at a lower centrifugation speed compared to
exosomes, which sediment at 100,000 g [43]. Since most
studies tend to sediment membranes at 100,000 g, any
preparation will likely contain both microvesicles and
exosomes, thus making it difficult to determine which of
these contribute to the effects observed [43]. Further-
more, it should also be noted that most published re-
search uses the term microvesicles to describe both of
Figure 2 Origin of microvesicles and exosomes from cells. A microvesicle arises from budding of the plasma membrane. Microvesicles are
more irregular in shape and size and can contain cytoplasmic materials. Microvesicles express surface markers such as integrin-β, CD40 and
selectins such as plasma selectins and/or proteins from the cells they originate from. Exosomes originate from the endosomal trafficking system
and, therefore, are more regular in shape and size. Exosomes are more easily identifiable via cell surface markers such as CD81, CD9 and CD63
and may contain materials such as mitochondrial DNAs, mRNAs and miRNAs. ER: endoplasmic reticulum; miRNA: microRNA; TGN: trans-Golgi
network; MVB: multi-vesicular bodies.
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tinct from apoptotic vesicles or bodies, which are shed
from normal and diseased cells undergoing apoptosis
[44].
Microvesicles derived from stem cells have already
been shown to contribute to tissue and cellular regen-
erative processes. Microvesicles isolated from MSCs
and EPCs have proliferative and anti-apoptotic effects
on tubular epithelial and endothelial cells in vitro,
in addition to being able to protect against AKI when
delivered in vivo to a glycerol-induced severe combined
immunodeficiency (SCID) mouse model [45] and
to an I/R injury rat model [46,47]. This regenerative ef-
fect was also found to be specific for MSC- and EPC-
derived microvesicles, as it was not observed with
fibroblast-derived microvesicles. Moreover, the effect
was abolished when the MSC- and EPC-derived mic-
rovesicles were treated with RNase prior to use, sug-
gesting that a form of RNA is a key player in their
reparative function [45,46].
This group of researchers also demonstrated the regen-
erative potential of microvesicles derived from human
liver stem cells [48]. They showed the proliferative and
anti-apoptotic properties of these human-derived
microvesicles on human and rat hepatocytes in vitro and
the regeneration and recovery of rat liver, when these
microvesicles were administered into 70% hepatectomised
rats [48]. They suggested that the microvesicles shuttle
mRNAs involved in angiogenic pathways and microRNAsassociated with cell proliferation, angiogenesis and inhib-
ition of apoptosis, to the damage sites [45,46].
Additionally, recently published work [49] using micro-
vesicles isolated from human umbilical cord MSCs, has
demonstrated in vitro that microvesicles can be in-
ternalised by endothelial cells and promote the proli-
feration and angiogenesis of these cells in culture.
Additionally, these researchers showed that this effect
could be translated to in vivo experiments using a rat hind
limb ischaemia model, whereby the exogenous micro-
vesicles were found to be able to promote new blood ves-
sel formation [49]. Further support for microvesicle/
exosome-mediated paracrine repair processes comes from
observations of the administration of MSC-derived exo-
somes to a murine model of hypoxic pulmonary hyper-
tension (HPH). This resulted in suppression of the
inflammatory processes, which are known to be a dam-
aging factor in the development of HPH [50].
The combined results from all these data, although at a
very early stage, have been encouraging in furthering our
understanding of how stem cells, and in particular
microvesicles, function in the body to initiate tissue repair.
These observations have provided a tantalising insight into
the possible use of microvesicles as a future cell-free ther-
apy for tissue repair.
Potential future treatment for regenerative medicine
Paracrine-mediated tissue repair might in future be
exploited via genetic engineering of stem, progenitor or
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stimulate regenerative processes in damaged tissues. A
number of researchers have looked at the potential of
introducing beneficial factors by modifying stem cells to
express these factors at the required level of efficacy.
One such study [51] looked at using modified MSCs to
express Wnt11; cardiomyocytes co-cultured with these
MSCs had increased cell survival and reduced cell death
following exposure to 40 hours of hypoxic conditions. In
addition, MSCWnt11 cell infusion in vivo improved car-
diac function in rats following MI, as well as reducing
apoptosis and fibrosis in the damaged hearts [51]. The
authors suggested that this was because the release of
Wnt11 caused regeneration of the damaged hearts, as
Wnt signalling has previously been reported to promote
cardiomyogenic repair [51]. A similar study employing
MSCs engineered to overexpress Akt also successfully
showed, in vitro and in vivo, the cytoprotective effects of
these engineered cells on ischaemic hearts [52].
Perhaps one of the more exciting novel therapeutic ap-
proaches is the development of non-cell-based therapies
for studying the effects that microvesicles derived from
various types of cells have on tissue regeneration.
Microvesicles as a source for drug therapy can be made
naturally, from either modified or unmodified regenera-
tive cells, as mentioned previously. This possibility was
demonstrated recently in an in vitro study [53] where
MSCs were modified to express cystinosin, the gene for
which (CTNS) is mutated in a rare disorder called
cystinosis, which causes a large accumulation of cysteine
in cells and eventually results in cellular apoptosis. It
was found that microvesicles isolated from CTNS-
expressing MSCs also contained CTNS mRNA and
when incubated with CTNS mutant fibroblasts (−/−),
resulted in reduced cysteine accumulation in the cells
[53]. Microvesicles may also be artificially manufactured
to incorporate therapeutic entities for the treatment of a
specific disease. This method may have certain advan-
tages for the manufacturing processes and stringent
quality control as well as because of the ability to design
custom-made microvesicles that express proteins,
mRNAs and/or microRNAs relevant to a particular dis-
ease or condition. Numerous ways in which micro-
vesicles can be manipulated for use in regenerative
medicine for organ and tissue regeneration and repair
have been extensively reviewed by Ratajczak et al. [54].
Conclusions
Although many details of cellular paracrine effects remain
to be elucidated, it is clear that the potential for the dis-
covery of novel therapies for regenerative medicine will
rise exponentially in the not too distant future and may ul-
timately result in such therapies being transferred from
the lab into the clinic. Indeed, this development is alreadybecoming a reality as currently two groups of researchers
have started phase 1 clinical trials using cardiosphere-
derived cells [55] and cardiac stem cells [56] to improve
patient outcomes following an episode of MI. The full re-
sults of the trials are very much anticipated by the rest of
the science and medical communities.
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